Prostate Cancer Market is expected to reach US$ 24.7 billion by 2033

The Global Prostate Cancer Market is expected to be worth around US$ 10.92 billion in 2023 and to grow at an 8.5% CAGR through 2033. By 2033, the market is expected to be worth US$ 24.7 billion

. Recent developments in drug development, an increasing number of drugs that have been approved by the FDA, and a high growth rate in the market for hormone-refractory glandular cancer medicines are expected to grow the market in the coming years.

In addition to an aging population, the high disposable income also contributes to the market’s growth. Growth will also be driven by rising cancer prevalence rates, the changing fashion habits of the population, an increase in patient awareness, and an increase in demand for non-invasive therapies.

Download Sample Copy: https://www.futuremarketinsights.com/reports/sample/rep-gb-16210

A number of different methods are available to treat this disease, including targeted or biological therapy, chemotherapy, and hormonal therapy. Further new studies are being approved by the FDA for therapies and drugs that are to be marketed in the near future. There is a recent study conducted by Moon Hyung Choi and co-workers suggests the use of pre-biopsy MRIs can effectively prevent unnecessary biopsies in people who have levels of prostate-specific antigen (PSA) in excess of 20 ng/ml.

Key Takeaways from the Market Study

According to the latest projections, the global prostate cancer market will grow by 8.5% by 2033 and reach US$ 24.7 Billion.
Online pharmacies are expected to capture 28% of the market for prostate cancer by 2023; this represents a huge growth.
The North American region accounted for 45% of the worldwide revenue generated by prostate cancer in 2023.
According to the predictions for 2023, Europe will hold 32% of the market share.
Among all of the medical treatments, chemotherapy is the leading market share with more than 12%.

“New drug development and therapies are being studied in greater numbers. At-home chemotherapy and oral chemotherapy are in high demand. A reimbursement scheme that covers affordable generics will reduce coverage for expensive therapies, says an analyst at FMI.

Speak to our Research Expert: https://www.futuremarketinsights.com/ask-question/rep-gb-16210

Competitive Landscape

The availability of oral chemotherapy is one of the major factors driving its demand. Rather than spending exorbitant amounts on medical expenses, preventative measures can be taken. To expand to more complex applications, companies with a wide geographic reach are taking collaborative measures to boost sales, including merging multiple businesses into one to provide more versatile medical products.

Competitors are consolidating their market presence through strategic, profitable partnerships. Companies can use advanced technology more effectively through acquisitions and partnerships. In order to expand their technology horizons, home health clinic companies enter into a number of deals.

Telix Pharmaceuticals Limited is pleased to announce that the results of its pivotal Phase III ZIRCON study for TLX250-CDx have been selected for oral presentation at the ASCO GU Symposium scheduled for February 16-18 2023 in San Francisco, CA. As part of the program, Telix will present six more presentations on its theranostic candidates targeting carbonic anhydrase IX (CAIX) and prostate-specific membrane antigens (PSMA). This presentation will discuss advances in prostate cancer PET imaging with PSMA-11, potential uses of TLX250-CDx outside ccRCC, and STARLITE Phase II studies, which are assessing whether TLX250 targeted radiation combined with immunotherapy will be effective in treating ccRCC.
An innovative medical technology company whose mission is to improve cancer surgery outcomes and support clinicians during intraoperative decisions, Samantree Medical announced the publication of a study on prostate cancer. Increasing the clinical use of the Histolog Scanner, the company’s proprietary imaging platform. Under the supervision of Professor Diederik Somford and Dr. Willem Vreuls, the Enclosure Study was conducted at Canisius Wilhelmina Hospital (Netherlands). As an alternative to NeuroSAFE, the Histolog Scanner was evaluated.

Request for Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-16210

Key Segments Profiled in the Prostate Cancer Industry Survey

Prostate Cancer Market by Drug Class:

Hormonal Prostate Cancer Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  - Zytiga
  - Gonax
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  - Lupron
  - Zoladex
  - Eligard
  - Decapeptyl
  - Vantas
  - Others
- Anti-Androgen
  - Xtandi
  - Casodex
Prostate Cancer Chemotherapy
- Taxotere
- Jevtana
Prostate Cancer Immunotherapy
- Provenge
Prostate Cancer Targeted Therapy
- Xofigo
Others Prostate Cancer

Prostate Cancer Market by Distribution Channel:

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

Prostate Cancer Market by Region:

North America Prostate Cancer Market
Latin America Prostate Cancer Market
Europe Prostate Cancer Market
South Asia & Pacific Prostate Cancer Market
East Asia Prostate Cancer Market
Middle East & Africa Prostate Cancer Market

More Trending Reports by Future Market Research:

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Prostate Cancer Market is expected to reach US$ 24.7 billion by 2033 | FMI

Leave a comment

Cancel reply